Testing Experimental Treatment for Frontotemporal Dementia
common.study.values.description
“A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients”
A Phase 2 open label study evaluating the safety, tolerability, PK and PD of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - AL001
administered via intravenous (IV) infusion once a month
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia
common.study.values.clinical-trial-id
NCT03987295
participant.views.study.view.id
bYE92b
